Results 191 to 200 of about 37,295 (243)
Clinical pharmacology of thalidomide
European Journal of Clinical Pharmacology, 2001 Background: Thalidomide has a chiral centre, and the racemate of (R)- and (S)-thalidomide was introduced as a sedative drug in the late 1950s. In 1961, it was withdrawn due to teratogenicity and neuropathy.
Tommy Eriksson +2 more
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Dermatologic Clinics, 2001
Thalidomide has been successful in the treatment of several dermatologic conditions unresponsive to other agents. Further experience may lead to a better understanding of its mechanism of action in these various diseases. Thalidomide should be considered an extremely valuable therapeutic option in selected patients when the benefits clearly outweigh ...
C L, Radomsky, N, Levine
openaire +2 more sources
Thalidomide has been successful in the treatment of several dermatologic conditions unresponsive to other agents. Further experience may lead to a better understanding of its mechanism of action in these various diseases. Thalidomide should be considered an extremely valuable therapeutic option in selected patients when the benefits clearly outweigh ...
C L, Radomsky, N, Levine
openaire +2 more sources
Nature, 1963
EARLY in 1962 Prof. Alexander Haddow suggested that we should test thalidomide for carcinogenicity. Accordingly, 20 male mice of the Chester Beatty stock strain were injected subcutaneously in the flank once weekly with 15-mg thalidomide suspended in 0.2 ml. arachis oil.
F J, ROE, B C, MITCHLEY
openaire +2 more sources
EARLY in 1962 Prof. Alexander Haddow suggested that we should test thalidomide for carcinogenicity. Accordingly, 20 male mice of the Chester Beatty stock strain were injected subcutaneously in the flank once weekly with 15-mg thalidomide suspended in 0.2 ml. arachis oil.
F J, ROE, B C, MITCHLEY
openaire +2 more sources
Australasian Journal of Dermatology, 2002
SUMMARYThalidomide is an effective agent to treat over 25 seemingly unrelated dermatological conditions that have an inflammatory or autoimmune basis. The main side‐effects of teratogenesis and peripheral neuropathy limit its use. Currently, in Australia no assurance is given as to the quality, safety and efficacy of thalidomide. The use of thalidomide
Nina Y, Wines +2 more
openaire +2 more sources
SUMMARYThalidomide is an effective agent to treat over 25 seemingly unrelated dermatological conditions that have an inflammatory or autoimmune basis. The main side‐effects of teratogenesis and peripheral neuropathy limit its use. Currently, in Australia no assurance is given as to the quality, safety and efficacy of thalidomide. The use of thalidomide
Nina Y, Wines +2 more
openaire +2 more sources
Pediatrics, 1962
THALIDOMIDE [alpha (N-phthalimido) glutarimide] is a synthetic drug with the structural formula shown in Figure 1. Thalidomide was invented by the firm of Chemie Grünenthal as a sedative, but when tested on animals was found to be ineffective. Chemie Grünenthal was, however, so certain that thalidomide must have some quieting effect on the central ...
openaire +2 more sources
THALIDOMIDE [alpha (N-phthalimido) glutarimide] is a synthetic drug with the structural formula shown in Figure 1. Thalidomide was invented by the firm of Chemie Grünenthal as a sedative, but when tested on animals was found to be ineffective. Chemie Grünenthal was, however, so certain that thalidomide must have some quieting effect on the central ...
openaire +2 more sources
Clinical Pharmacology & Therapeutics, 1973
The association between thalidomide and phocomelia was discovered because of the rarity of phocomelia. When we give a drug to a pregnant woman we are also giving it to the fetus whether we want to or not. We must therefore insist that every precaution be taken to identify possible harm to the fetus before any new drug is released.
openaire +2 more sources
The association between thalidomide and phocomelia was discovered because of the rarity of phocomelia. When we give a drug to a pregnant woman we are also giving it to the fetus whether we want to or not. We must therefore insist that every precaution be taken to identify possible harm to the fetus before any new drug is released.
openaire +2 more sources
International Journal of Biochemistry and Cell Biology, 2007
Over the past 50 years, thalidomide has been a target of active investigation in both malignant and inflammatory conditions. Although initially developed for its sedative properties, decades of investigation have identified a multitude of biological effects that led to its classification as an immunomodulatory drug (IMiD). In addition to suppression of
Magda, Melchert, Alan, List
exaly +3 more sources
Over the past 50 years, thalidomide has been a target of active investigation in both malignant and inflammatory conditions. Although initially developed for its sedative properties, decades of investigation have identified a multitude of biological effects that led to its classification as an immunomodulatory drug (IMiD). In addition to suppression of
Magda, Melchert, Alan, List
exaly +3 more sources
Drug News & Perspectives, 2002
The first paper describing the pharmacological actions of thalidomide was published in 1956. The drug, then designated as K17, was thought to have sedative effects superior to those of comparator drugs and was thought to be virtually nontoxic. Only 2 years after thalidomide's launch as Contergan in Germany, it's alleged lack of toxicity came into ...
openaire +2 more sources
The first paper describing the pharmacological actions of thalidomide was published in 1956. The drug, then designated as K17, was thought to have sedative effects superior to those of comparator drugs and was thought to be virtually nontoxic. Only 2 years after thalidomide's launch as Contergan in Germany, it's alleged lack of toxicity came into ...
openaire +2 more sources
BioDrugs, 1999
The major therapeutic effects of thalidomide are the selective inhibition of tumour necrosis factor-alpha production by monocytes and alteration in cellular surface expression of integrins. The major drawbacks of the drug are teratogenicity and irreversible axonal neuropathy.
openaire +2 more sources
The major therapeutic effects of thalidomide are the selective inhibition of tumour necrosis factor-alpha production by monocytes and alteration in cellular surface expression of integrins. The major drawbacks of the drug are teratogenicity and irreversible axonal neuropathy.
openaire +2 more sources